蛋白激酶C参与缺氧预处理的血管平滑肌细胞保护

已知缺氧预处理不仅对心肌细胞,而且对血管床亦有保护作用;但对血管壁细胞是否有直接保护作用,目前尚不清楚。本工作在培养的家兔血管平滑肌细胞（ＶＳＭＣ）缺氧复氧（Ａ／Ｒ）损伤模型上观察缺氧预处理（ａｎｏｘｉｃｐｒｅｃｏｎｄｉｔｉｏｎｉｎｇ,ＡＰＣ）的影响。发现ＡＰＣ能提高Ａ／Ｒ后ＶＳＭＣ存活率,减轻细胞脂质过氧化损伤和钙超载,使用蛋白激酶Ｃ（ＰＫＣ）激动剂ＰＭＡ能模拟,而抑制剂Ｈ７或ｐｏｌｙｍｙｘｉｎＢ能完全消除ＡＰＣ的上述保护作用。提示ＡＰＣ对ＶＳＭＣ的Ａ／Ｒ损伤具有保护作用,其机理可能与ＰＫＣ激活有关     

碱性成纤维细胞生长因子对乳鼠心肌细胞缺氧复氧损伤的影响

本实验在培养的乳鼠心肌细胞缺氧复氧损伤模型上观察碱性纤维细胞生长因子对Ａ／Ｒ损伤及蛋白激酶活性的影响,以探讨ｂＥＧＦ作为药物预处理心肌保护的可行性及其机理。结果表明,ｂＥＧＦ预处理呈浓度依赖地提高Ａ／Ｒ后心肌细胞存活率,减少细胞内ＡＴＰ消耗及胞浆乳酸脱氢酶漏出;ＰＫＣ抑制剂Ｈ７完全消除ｇＦＧＦ的上述保护作用;实验结果表明,ｂＦＧＦ可以直接激活心肌细胞ＰＫＣ,其激活时相的变化与缺氧预处理者相近,提示     

谷氨酰胺对体外培养人小肠上皮细胞缺氧复氧损伤的保护作用

应用原代培养人胎小肠上皮细胞（ＩＥＣ）,观察了谷氨酰胺（ＧＬＮ）对缺氧复氧（Ａ／Ｒ）损伤人ＩＥＣ的影响。结果：缺氧６０ｍｉｎ复氧３０ｍｉｎ后,细胞内乳酸脱氢酶（ＬＤＨ）漏出量显著上升,细胞存活率显著下降。预先应用１～５ｍｍｏｌ／ＬＧＬＮ可使Ａ／Ｒ损伤ＩＥＣ细胞存活率升高和细胞内ＬＤＨ漏出量减少,ＧＬＮ作用的最佳剂量为２ｍｍｏｌ／Ｌ。提示ＧＬＮ对人ＩＥＣ具有直接的保护作用,这可能是其整体保护作用机制之一。     

短暂低氧／复氧对培养新生兔心肌细胞丝裂素活化蛋白激酶活性的影响

心肌细胞短暂低氧可诱导对后续长时间低氧所致细胞严重损伤的耐力增强,已在心脏预处理（ＰＣ）模型上得到证实,但ＰＣ发生的细胞内信号传导途径目前尚不清楚。我们在培养的新生兔心肌细胞低氧／复氧模型上,观察丝裂素活化蛋白激酶（ＭＡＰＫ）和核蛋白体Ｓ６激酶（Ｓ６Ｋ）活性改变。结果发现：低氧６０ｍｉｎ后、复氧１５ｍｉｎ,细胞总ＭＡＰＫ和核ＭＡＰＫ活性分别较对照组增加９５％和２３０％（Ｐ〈０．０１）;Ｓ６Ｋ活性在     

蛋白激酶C和Na~＋－H~＋交换在ANGⅡ诱发心肌细胞肥大反应中的作用

血管紧张素（ＡＮＧ）Ⅱ在１０－１０－１０－６ｍｏｌ／Ｌ范围内剂量依赖性促进无血清培养新生大鼠心肌细胞蛋白质合成速率。蛋白激酶Ｃ（ＰＫＣ）抑制剂ｓｔａｕｒｏｓｐｏｒｉｎｅ（Ｓｔａｕ２ｎｍｏｌ／Ｌ）对心肌细胞基础状态３Ｈ－Ｌｅｕｃｉｎｅ掺入无明显影响，但Ｓｔａｕ预处理３０ｍｉｎ，则可有效阻断ＡＮＧⅡ（１μｍｏｌ／Ｌ）对细胞蛋白质合成的刺激作用；单纯应用ＰＫＣ激活剂ＰＭＡ（１μｍｏｌ／Ｌ）可使心肌细胞蛋白质合成速率增加，与对照组相比，ＰＭＡ组３Ｈ－Ｌｅｕｃｉｎｅ掺入量增加了４１．０４％。细胞Ｎａ＋－Ｈ＋交换抑制剂Ａｍｉｌｏｒｉｄｅ预处理也能阻断ＡＮＧⅡ刺激３Ｈ－Ｌｅｕｃｉｎｅ掺入细胞蛋白质的作用。以上结果提示ＰＫＣ和Ｎａ＋－Ｈ＋交换的激活，可能是ＡＮＧⅡ诱发的心肌细胞肥大反应的重要胞内信息转导机制。本工作还观察到，阻断细胞Ｎａ＋－Ｈ＋交换后并不影响由ＰＫＣ激活导致的蛋白质合成增加，提示可能存在着ＰＫＣ和Ｎａ＋－Ｈ＋交换彼此相对独立地调节心肌细胞生长的途径。     

参麦注射液抗心肌缺氧-再给氧损伤实验研究

采用Ｌａｎｇｅｎｄｏｒｆ离体心脏灌注模型,对大鼠心肌缺氧—再给氧损伤中抗自由基酶ＳＯＤ和ＧＳＨ－Ｐｘ,过氧化产物ＭＤＡ、心肌酶ＣＰＫ和心肌细胞超微结构进行了观察、同时探讨了参麦注射液的保护作用机理。结果表明：（１）心肌缺氧灌注４０ｍｉｎ,富氧再灌５ｍｉｎ,与正常对照组比较,心肌细胞超微结构损伤严重,线粒体数目减少,大部分空泡变性,嵴消失,糖原颗粒减少,心肌收缩结构受到严重破坏。同时ＣＰＫ活性明显升高,ＳＯＤ及ＧＳＨ－Ｐｘ活性明显降低,ＭＤＡ含量明显升高（Ｐ＜０．０１）。（２）预先给不同剂量参麦注射液进行灌注,与模型组比较,心肌超微结构损伤明显减轻,线粒体数目较多,嵴密集,未见肿胀变形,糖原颗粒丰富,心肌收缩结构基本正常。ＣＰＫ活性明显降低,心肌ＳＯＤ及ＧＳＨ－Ｐｘ活性明显增高,心肌ＭＤＡ含量明显降低（Ｐ＜０．０１）。且参麦大剂量组疗效优于复方丹参液（Ｐ＜０．０５）。我们推测其保护作用机理可能是稳定心肌细胞膜,保护心肌线粒体,增加能量供应,提高抗自由基酶活性,从而减轻氧自由基对心肌的损害     

核受体辅助因子及其信号转导

类固醇激素、核受体及其辅助因子在细胞增殖、分化中起重要的作用。核受体与相应的配体结合后同细胞内的辅助激活因子ＣＢＰ／Ｐ３００、ＰＣＡＦ、Ｐ／ＣＩＰ和ＳＲＣ家族等结合形成的复合物能使组蛋白乙酰化促进基因的转录,当缺乏配体时核受体同辅助抑制因子ＳＭＲＩ、mSin3A及ＨＡＤ１具有很强的结合力使组蛋白去乙酰化抑制基因的转录活性。ＭＡＰＫ、ＰＫＡ、ＡＰ－１、Ｓap-a、ＪＡＫ／ＳＴＡＴ、ＪＡＫ信号传导中核受体辅助因子参与信号传导过程影响基础的转录。     

蛋白激酶C的激活转位和它介导的信号通路

蛋白激酶Ｃ是一系列丝氨酸／苏氨酸蛋白激酶家族,已发现了至少十二种同功酶。在静止细胞中,它主要以非活化形式存在于胞浆中,由受体－Ｇ蛋白耦联的ＰＬＣβ激活便裂细胞膜上的磷脂而释放ＤＡＧ;与ＰＫＣ的结合引起了ＰＫＣ的别构激活;而通过其它信号途径激活的ＰＬＤ水解胞膜的磷脂酰胆碱（ＰＣ）产生的磷脂酸经磷脂酸酯酶产生的ＤＡＧ可能是ＰＫＣ持续激活的必要条件。在体外实验中,ＰＫＣ的持续激活是一些细胞分化所必须的。蛋白激酶Ｃ的激活首先引起了它转位到膜,有时转位到核,并在转位后继续保持磷酸化活性,同时对它的下游底物进行磷酸化导致它们的活化。ＰＫＣ可活化ＲａｆＳｅｒ／Ｔｈｒ蛋白激酶及ＮＦ－ｋＢ,介导细胞对外界的反应,包括对核基因表达的调节,引起细胞生长或分化等。由于Ｒａｆ可与活化的Ｒａｓ—ＧＴＰ结合从而定位到胞膜,说明蛋白激酶Ｃ与Ｒａｓ介导的Ｒａｆ－１／ＭＥＫ／ＭＡＰＫ信号通路间存在着“对话”。     

MAPK对胰岛素介导的人血管平滑肌细胞PKCα的影响

目的：在胰岛素的干预下,观察ＭＡＰＫ反义寡核苷酸（ＯＤＮｓ）对人血管平滑肌细胞（ＶＳＭＣ）增殖及ＰＫＣα表达的影响。方法：３ＨＴｄＲ掺入法检测ＶＳＭＣ增殖,逆转录ＰＣＲ、免疫组织化学法检测ＰＫＣα表达。结果：反义ＯＤＮｓ 处理的细胞可显著抑制胰岛素诱导的ＶＳＭＣ的ＤＮＡ合成,ＯＤＮｓ 的上述作用与降低ＶＳＭＣ内ＰＫＣα基因表达有关。结论：胰岛素刺激人ＶＳＭＣ增殖可被ＭＡＰＫ反义寡核苷酸所抑制,可能存在有关胰岛素ＰＫＣＭＡＰＫ激活途径     

苏云金芽胞杆菌以色列亚种20kDa蛋白质对CytA蛋白溶细胞作用的影响

为了证明苏云金芽胞杆菌以色列亚种２０ｋＤｅ蛋白质对ＣｙｔＡ蛋白溶细胞作用的影响, 根据２０ｋＤｅ蛋白质和ｃｙｔＡ蛋白基因的核苷酸序列,用ＡＭＰＬＩＦＹ程序设计了一套带有酶切位 点的引物,经ＰＣＲ扩增分别获得了２０ｋＤｅ蛋白质和ｃｙｔＡ蛋白基因。将其基因与表达载体 ｐＵＨＥ２４连接并转化到大肠杆菌ＸＬＩ和ＤＨＳ 分别获得含２０ｋＤａ蛋白质基因的克隆子 ＬＺ２９;含ｃｙｔＡ基因的克隆子ＬＺｃｙｔＡ和含有二者基因的重组子ＬＺ２０Ａ．在ＩＰＴＧ诱导下,测定 了不同克隆株基因表达产物对大肠杆菌细胞生长的影响。结果表明：ＬＺ２０的细胞生长不受影 响;ＬＺｃｙｔＡ的细胞被杀死;ＬＺ２０Ａ的细胞生长也不受影响。这表明２０ｋＤａ蛋白质基因与ｃｙｔＡ 蛋白基因重组后,２０ｋＤａ蛋白质基因表达产物可保护ＣｙｔＡ蛋白对大肠杆菌的溶细胞作用,而 巳这种作用并不因不同大肠杆菌受体而改变。     

The protective effects of puerarin in cardiomyocytes from anoxia/reoxygenation injury are mediated by PKCε

Puerarin is an isoflavone isolated from traditional Chinese medicine Ge‐gen (Radix Puerariae). Clinical studies have confirmed the cardioprotective effects of puerarin; however, the mechanisms underlying these effects are still unclear. On the basis of previous findings, we hypothesized that puerarin protects cardiomyocytes from ischemia–reperfusion injury via the protein kinase C epsilon (PKCε) (a critical cardioprotective protein) signalling pathway. Neonatal rat primary cardiomyocytes were preconditioned with puerarin or puerarin plus εV1‐2, a selective PKCε inhibitor, prior to anoxia/reoxygenation (A/R) treatment. Western blot analysis showed that expression and activity of PKCε protein in puerarin preconditioned group were both increased compared with the control or A/R group. Subsequent assays showed that preconditioning with puerarin could increase the viability of neonatal rat primary cardiomyocytes treated with A/R, decreased the generation of reactive oxygen species (ROS), loss of mitochondrial membrane potential, cell necrosis and apoptosis induced by A/R injury. However, the protective effects of puerarin completely disappeared in the group pretreated with puerarin plus εV1‐2. Thus, for the first time, we revealed the protective effects of puerarin in cardiomocytes from anoxia/reoxygenation injury are mediated by PKCε. Copyright © 2014 John Wiley & Sons, Ltd.     

Role of protein phosphatases in hypoxic preconditioning

To find a protein kinase C (PKC)-independent preconditioning mechanism, hypoxic preconditioning (HP; i.e., 10-min anoxia and 10-min reoxygenation) was applied to isolated rat hearts before 60-min global ischemia. HP led to improved recovery of developed pressure and reduced end-diastolic pressure in the left ventricle during reperfusion. Protection was unaffected by the PKC inhibitor bisindolylmaleimide (BIM; 1 micromol/l). It was abolished by the inhibitor of protein phosphatases 1 and 2A cantharidin (20 or 5 micromol/l) and partially enhanced by the inhibitor of protein phosphatase 2A okadaic acid (5 nmol/l). In adult rat cardiomyocytes treated with BIM and exposed to 60-min simulated ischemia (anoxia, extracellular pH 6.4), HP led to attenuation of anoxic Na(+)/Ca(2+) overload and of hypercontracture, which developed on reoxygenation. This protection was prevented by treatment with cantharidin but not with okadaic acid. In conclusion, HP exerts PKC-independent protection on ischemic-reperfused rat hearts and cardiomyocytes. Protein phosphatase 1 seems a mediator of this protective mechanism.     

The effects of quercetin protect cardiomyocytes from A/R injury is related to its capability to increasing expression and activity of PKCε protein

Quercetin is a ubiquitous flavonoid found in vegetable foods. Epidemiological and animal studies have reported an inverse association between quercetin intakes and occurrence and development of various cardiovascular diseases. Some researchers have inferred that the mechanisms of quercetin to protect cardiomyocytes from ischemia/reperfusion injury may be involved in modulation of intracellular signal pathways and regulation of proteins expression beyond its antioxidant activity. The aim of this study was to investigate whether quercetin protect cardiomyocytes from anoxia/reoxygenation injury through PKCε pathway. Neonatal rat primary cardiomyocytes were pretreated with quercetin or quercetin plus εV1-2, a selective PKCε inhibitor, prior to A/R treatment. Western blotting analysis showed that the level of PKCε and phosphor-PKCε Ser297 in the quercetin pretreatment group were all increased significantly compared to the control or A/R group. Subsequent assays showed that pretreated with quercetin could increase the viability of neonatal rat primary cardiomyocytes suffered A/R, decrease the apoptosis and ROS and alleviate the loss of mitochondrial membrane potential induced by A/R injury. However, the protective effects of quercetin disappeared in the group pretreated with εV1-2. Thus, for the first time, we revealed that one of the mechanisms of quercetin protecting cardiomyocytes from A/R injury might be increase the expression of PKCε protein and then enhance the activity of its downstream pathway.     

p38 MAPKα/β和ERK1/2在心肌缺氧预处理信号传递中的不同作用

建立培养乳鼠心肌细胞的缺氧／复氧(A／R)损伤模型和缺氧预处理(APC)模型,以细胞存活率、细胞内超氧化物趋化酶(SOD)活性、丙二醛(MDA)含量、培养上清液乳酸脱氢酶(LDH)活性作为反映心肌细胞损伤的指标。采用细胞外信号调节蛋白激酶(ERK1／2)抑制剂PD98059及丝裂素活化蛋白激酶p38α/β(p38α/β)阻滞剂SB203580干预模型,并以胶内原位磷酸化法测定ERK1／2和p38活性,借以探讨ERK1／2和p38α/β在缺氧预处理保护机制中的作用。结果表明：(1)在APC组,于预处理的缺氧时相给予PD98059,可以完全消除APC的延迟保护作用;在A／R组的缺氧时相加入PD98059对细胞损伤无影响;(2)在APC组的预处理缺氧时相给予p38α／β抑制剂SB203580并不能消除APC的保护作用,而在A／R组的持续缺氧时相给予SB203580则可显著减轻缺氧对细胞的损伤;(3)ERK1／2和p38总活性测定表明,缺氧可激活ERK1／2和p38,它们的活性在缺氧后4h时达到高峰,而经过APC处理后,两者活性高峰提前于缺氧后3h时出现,且峰值显著降低。上述结果提示,预处理过程中ERK1／2的激活可能是缺氧预处理延迟保护机制中细胞信号传递的重要环节,预处理阶段p38α/β的活化不参与APC诱导的延迟保护信号传递过程,p38的过度激活可能是缺氧／复氧损伤过程中的一个致损伤参与因素,而预处理抑制随后持续缺氧阶段p38的过度激活可能是其保护机制的一个环节。     

Hypothermia-induced cardioprotection using extended ischemia and early reperfusion cooling

Optimal timing of therapeutic hypothermia for cardiac ischemia is unknown. Our prior work suggests that ischemia with rapid reperfusion (I/R) in cardiomyocytes can be more damaging than prolonged ischemia alone. Also, these cardiomyocytes demonstrate protein kinase C (PKC) activation and nitric oxide (NO) signaling that confer protection against I/R injury. Thus we hypothesized that hypothermia will protect most using extended ischemia and early reperfusion cooling and is mediated via PKC and NO synthase (NOS). Chick cardiomyocytes were exposed to an established model of 1-h ischemia/3-h reperfusion, and the same field of initially contracting cells was monitored for viability and NO generation. Normothermic I/R resulted in 49.7 +/- 3.4% cell death. Hypothermia induction to 25 degrees C was most protective (14.3 +/- 0.6% death, P < 0.001 vs. I/R control) when instituted during extended ischemia and early reperfusion, compared with induction after reperfusion (22.4 +/- 2.9% death). Protection was completely lost if onset of cooling was delayed by 15 min of reperfusion (45.0 +/- 8.2% death). Extended ischemia/early reperfusion cooling was associated with increased and sustained NO generation at reperfusion and decreased caspase-3 activation. The NOS inhibitor N(omega)-nitro-L-arginine methyl ester (200 microM) reversed these changes and abrogated hypothermia protection. In addition, the PKCepsilon inhibitor myr-PKCepsilon v1-2 (5 microM) also reversed NO production and hypothermia protection. In conclusion, therapeutic hypothermia initiated during extended ischemia/early reperfusion optimally protects cardiomyocytes from I/R injury. Such protection appears to be mediated by increased NO generation via activation of protein kinase Cepsilon; nitric oxide synthase.     

Crosstalk between adenosine A1 and β1-adrenergic receptors regulates translocation of PKCε in isolated rat cardiomyocytes

Adenosine A(1) receptor (A(1)R)-induced translocation of PKCε to transverse (t) tubular membranes in isolated rat cardiomyocytes is associated with a reduction in β(1)-adrenergic-stimulated contractile function. The PKCε-mediated activation of protein kinase D (PKD) by endothelin-1 is inhibited by β(1)-adrenergic stimulated protein kinase A (PKA) suggesting a similar mechanism of A(1)R signal transduction modulation by adrenergic agonists may exist in the heart. We have investigated the influence of β(1)-adrenergic stimulation on PKCε translocation elicited by A(1)R. Immunofluorescence imaging and Western blotting with PKCε and β-COP antibodies were used to quantify the co-localization of PKCε and t-tubular structures in isolated rat cardiomyocytes. The A(1)R agonist CCPA increased the co-localization of PKCε and t-tubules as detected by imaging. The β(1)-adrenergic receptor agonist isoproterenol (ISO) inhibited this effect of CCPA. Forskolin, a potent activator of PKA, mimicked, and H89, a pharmacological PKA inhibitor, and PKI, a membrane-permeable PKA peptide PKA inhibitor, attenuated the negative effect of ISO on the A(1)R-mediated PKCε translocation. Western blotting with isolated intact hearts revealed an increase in PKCε/β-COP co-localization induced by A(1)R. This increase was attenuated by the A(1)R antagonist DPCPX and ISO. The ISO-induced attenuation was reversed by H89. It is concluded that adrenergic stimulation inhibits A(1)R-induced PKCε translocation to the PKCε anchor site RACK2 constituent of a coatomer containing β-COP and associated with the t-tubular structures of the heart. In that this translocation has been previously associated with the antiadrenergic property of A(1)R, it is apparent that the interactive effects of adenosine and β(1)-adrenergic agonists on function are complex in the heart.     

The role of actin depolymerizing factor in advanced glycation endproducts-induced impairment in mouse brain microvascular endothelial cells

Orexin-A, which is an endogenous neuropeptide, is reported to have a protective role in ischemic stroke. High-concentration glutamic acid (Glu) induced by hypoxia injury in ischemic stroke can be inhibited by glial glutamate transporter GLT-1 which is only expressed in astroglia cells. A previous study reported that Orexin-A may regulate GLT-1 expression. However, the role of orexin-A in the regulation of GLT-1 in ischemic stroke still remains unclear. In this study, we aimed to investigate the effect and the underlying mechanism of orexin-A on Glu uptake in astrocytes in vitro and this effect on protecting the neurons from anoxia/hypoglycemic injury. The expression of GLT-1 significantly increased in the astrocytes with orexin-A treatment under anoxia/hypoglycemic conditions, promoting the uptake of Glu and inhibiting the apoptosis of co-cultured cells of astrocytes and neurons. However, these effects were significantly weakened by treatment with orexin-A receptor 1 (OX1R) antagonist. Orexin-A significantly up-regulated the expressions of PKCα and ERK1/2 under anoxia/hypoglycemic conditions in astrocytes, whereas the OX1R antagonist markedly reversed the effect. Furthermore, PKCα or ERK1/2 inhibitor significantly constrained the GLT-1 expression in astrocytes and facilitated the apoptosis of co-cultured cells, and GLT-1 overexpression could reverse those effects of PKCα or ERK1/2 inhibitor. Taken together, orexin-A promoted the GLT-1 expression via OX1R/PKCα/ERK1/2 pathway in astrocytes and protected co-cultured cells against anoxia/hypoglycemic injury.